Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AREN1921 : Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

<30Age Under 30

Urinary System<br/>CancersCancer LocationUrinary System
Cancers

Systemic therapy | Urinary systemWilm's tumour

Trial Overview Read MoreRead more

This phase II trial is evaluating the effects of different combinations of chemotherapy (UH-3 and ICE/Cyclo/Topo) in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's Tumour (DAWT) or favourable histology Wilm's Tumour (FHWT) that has come back (relapsed).
 

This trial is treating patients with Wilm's tumour.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Cooperative Group

Children's Oncology Group

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

This is a non-randomised trial with two experimental arms. Participants with new diagnosed diffuse anaplastic Wilm's Tumour (DAWT) will receive a regimen of UH-3, consisting of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with favourable histology Wilm's Tumour (FHWT) that has come back (relapsed) will receive a regimen of ICE/Cyclo/Topo, consisting of ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan.

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next